News and Events

News

Patient and Healthcare Provider Convenience Focus of Packaging Enhancements for Humate-P from CSL Behring
November 9, 2009
Read Press Release

National Hemophilia Foundation Applauds First von Willebrand Disease Clinical Practice Guidelines Issued by NHLBI
May 6, 2008
Read Press Release

Humate-P^® Package Notification
Wednesday, July 25, 2007
Read Press Release

Humate-P^® Approved to Prevent Excessive Bleeding in VWD Patients
Undergoing Surgery
Monday, April 30, 2007
Read Press Release
Updated Prescribing Information

CSL Behring Announces Availability of Humate-P^® with Smaller Diluent
Wednesday, February 15, 2006
Read Press Release

Events

To stay informed about the latest news in bleeding disorders, you or your patients may be interested in attending the conferences and meetings listed below. CSL Behring will be participating in all of these events, so please stop by our exhibit booth and get information on Humate-P^®, speak with a CSL Behring representative, or obtain brochures.

Hemophilia & Thrombosis Research Society
2009 HTRS/NASCOLA Annual Scientific Symposium
April 15-17, 2010
Chicago, IL
www.htrs.org

Hemophilia Federation of America
HFA 2010 Annual Meeting and Educational Symposium
April 22-24, 2010
Westin Crown Center
1 East Pershing Road
Kansas City, MO
www.hemophiliafed.org

World Federation of Hemophilia
July 10-14, 2010
La Rural Convention & Exhibition Centre
Av. Sarmiento 2704
Buenos Aires, Argentina

National Hemophilia Foundation
Annual Meeting
November 11-13, 2010
New Orleans, LA
www.hemophilia.org

American Society of Hematology (ASH)
52nd ASH Annual Meeting and Exposition
December 4-7, 2010
Orange County Convention Center
Orlando, FL
http://www.hematology.org/

^*Upcoming conference dates will be posted when they become available.

Most local hemophilia chapters have a Web site, which typically includes a calendar of events. To find a chapter near you, go to the National Hemophilia Foundation Web site at: www.hemophilia.org/chapters

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.